文献速递肾小球疾病慢性肾脏病

血清多配体蛋白聚糖-1与特发性肾病综合征的肾脏及心血管结局相关

Serum Syndecan-1 is Associated With Kidney and Cardiovascular Outcomes in Idiopathic Nephrotic Syndrome.
PubMed 文献 · Kidney Int Rep · 2025-05-06

研究纳入NEPTUNE队列348例特发性肾病综合征(INS)患者及34名健康对照,检测基线血清多配体蛋白聚糖-1水平,发现其与肾脏复合结局(肾功能下降40%或肾衰竭)及血脂异常相关;体外实验显示INS复发血清可上调人肾小球内皮细胞多配体蛋白聚糖-1表达,地塞米松或金属蛋白酶抑制剂可部分或完全逆转。

要点

  • 血清多配体蛋白聚糖-1在INS患者中高于对照,约三分之一无蛋白尿或亚肾病范围蛋白尿患者中亦升高。
  • 接受类固醇治疗者(无论疾病活动度)多配体蛋白聚糖-1高于未用免疫抑制者。
  • 纵向分析中血清多配体蛋白聚糖-1与肾功能下降40%或肾衰竭的复合结局及血脂异常相关。

核心结论

  • 基线血清多配体蛋白聚糖-1与INS的不良肾脏结局及心血管危险因素相关。

研究设计与样本

  • 纳入NEPTUNE队列348例儿童和成人INS患者(35例未活检,141例微小病变型肾病[MCD],172例局灶节段性肾小球硬化[FSGS])及34名健康对照(22名成人,12名儿童)。
  • 采用酶联免疫吸附试验测定基线血清多配体蛋白聚糖-1水平,评估其与肾脏及心血管结局的关系。
  • 进行体外研究,检测INS血清及不同治疗药物对人肾小球内皮细胞(GEnC)多配体蛋白聚糖-1表达的影响。

主要发现

  • INS患者血清多配体蛋白聚糖-1高于对照,约三分之一无蛋白尿或亚肾病范围蛋白尿的患者中亦升高。
  • 接受类固醇治疗者(无论疾病活动度)多配体蛋白聚糖-1高于未用免疫抑制者。
  • 蛋白尿性MCD患者多配体蛋白聚糖-1高于FSGS患者。
  • 血清采集时,多配体蛋白聚糖-1与蛋白尿呈轻度相关,但与肾功能不相关。
  • 纵向分析中,血清多配体蛋白聚糖-1与肾功能下降40%或肾衰竭的复合结局及血脂异常相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Idiopathic nephrotic syndrome (INS) is associated with important kidney and cardiovascular morbidities. We tested the hypothesis that serum syndecan-1, a marker of endothelial glycocalyx injury, can help identify patients at risk for unfavorable kidney and cardiovascular outcomes. METHODS: We included 348 children and adults with INS (n = 35 unbiopsied, n = 141 minimal change disease [MCD] and n = 172 focal segmental glomerulosclerosis [FSGS]) from the Nephrotic Syndrome Study Network (NEPTUNE) cohort and 34 healthy participants (n = 22 adults, n = 12 children). We measured baseline serum syndecan-1 levels using an enzyme-linked immunosorbent assay and evaluated their relationship with kidney and cardiovascular outcomes. We performed in vitro studies to test whether INS sera and different therapeutics may alter syndecan-1 expression in human glomerular endothelial cells (GEnC). RESULTS: Serum syndecan-1 was higher in patients with INS than in controls and was high in approximately one-third of patients without proteinuria or with subnephrotic proteinuria. Patients receiving steroids, regardless of disease activity, showed higher syndecan-1 than those off immunosuppression. Syndecan-1 was higher in proteinuric patients with MCD than in FSGS. At the time of serum collection, syndecan-1 modestly correlated with proteinuria but not with kidney function. In longitudinal analyses, serum syndecan-1 was associated with the composite of 40% decline in kidney function or kidney failure and with dyslipidemia. Compared with controls, INS sera in relapse increased syndecan-1 expression in cultured GEnC, and this was partially or fully mitigated when dexamethasone or a metalloprotease inhibitor were added, respectively, to culture media. CONCLUSION: Baseline serum syndecan-1 is associated with unfavorable kidney outcomes and cardiovascular risk factors in INS.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Bauer C, Anand A, Sethna C, et al. Serum Syndecan-1 is Associated With Kidney and Cardiovascular Outcomes in Idiopathic Nephrotic Syndrome. Kidney Int Rep. 2025. PMID: 40814613. doi:10.1016/j.ekir.2025.04.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。